Onconova announces upcoming poster presentations at the AACR annual meeting

Onconova Therapeutics announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research, AACR, Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 – 19, 2023. Poster Title: Synergistic activity of the CDK4/6 antagonist narazaciclib with irreversible BTK inhibition in ibrutinib-resistant mantle cell lymphoma. This poster will describe studies evaluating narazaciclib in preclinical models of mantle cell lymphoma. Results from these studies demonstrated narazaciclib’s single-agent antitumor activity in MCL cell lines independent of their sensitivity to ibrutinib, which is a Bruton’s tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration for the treatment of MCL. When combining narazaciclib with ibrutinib, synergistic increases in antitumor activity against both BTKi-resistant and BTKi-sensitive MCL cell lines were observed. Poster Title: Differential targets engaged by narazaciclib in comparison to the approved CDK4/6 inhibitors contribute to enhanced inhibition of tumor cell growth. This poster will describe cell-based, in vitro, and bioinformatic analyses comparing narazaciclib and palbociclib. Results from a cell-based murine mammary carcinoma model showed a stronger induction of programmed cell death with narazaciclib compared to palbociclib. The results of additional cell-based assays that will be described in the poster suggest that narazaciclib may promote antitumor immunity and show that combining narazaciclib with autophagy inhibitors sensitizes breast cancer cells to cell death.